Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Non-Current Assets (2016 - 2025)

BioCorRx's Non-Current Assets history spans 15 years, with the latest figure at $6.1 million for Q3 2025.

  • For Q3 2025, Non-Current Assets rose 1990.14% year-over-year to $6.1 million; the TTM value through Sep 2025 reached $18.7 million, up 1841.49%, while the annual FY2024 figure was $267945.0, 32.8% up from the prior year.
  • Non-Current Assets for Q3 2025 was $6.1 million at BioCorRx, down from $6.2 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $6.2 million in Q1 2025 and bottomed at $165851.0 in Q1 2024.
  • The 5-year median for Non-Current Assets is $486213.0 (2022), against an average of $1.3 million.
  • The largest annual shift saw Non-Current Assets crashed 55.13% in 2023 before it soared 3659.57% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $591649.0 in 2021, then decreased by 23.99% to $449684.0 in 2022, then plummeted by 55.13% to $201768.0 in 2023, then skyrocketed by 32.8% to $267945.0 in 2024, then surged by 2165.87% to $6.1 million in 2025.
  • Per Business Quant, the three most recent readings for BICX's Non-Current Assets are $6.1 million (Q3 2025), $6.2 million (Q2 2025), and $6.2 million (Q1 2025).